Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PARG | Q86W56 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203266 | 0.80 | PLG (0.43) | PLAUSMN1; SMN2PLGPARG | |
| SCHEMBL3377342 | 0.78 | CHEK1 (0.43) | HTR2CHTR2AEGFRSMN1; SMN2PARG | |
| SCHEMBL23902742 | 0.72 | HTR6 (0.54) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL30241516 | 0.72 | HTR6 (0.54) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL29263685 | 0.71 | MAOB (0.42) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL3509678 | 0.71 | PRKCI (0.41) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL30365023 | 0.71 | PRKCI (0.41) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL31036110 | 0.71 | MAOB (0.42) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL4197546 | 0.71 | TLR7 (0.43) | PRKCIEGFRHTR6PLAUNTSR1 | |
| SCHEMBL218056 | 0.71 | PRKCI (0.58) | PRKCIHTR2CHTR2AEGFRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | PRKCI 1133/4885HTR2C 1229/4885HTR2A 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.